To study the regulatory mechanism of allergen-dependent human IgE synthesis, Cry j I-specific and interleukin 4 (IL-4)-producing CD4+ T cell lines (SN-4 and SS-12) were established from 2 patients allergic to Japanese cedar pollen who highly expressed IL-4 mRNA in T cells in response to Cry j I stimulation. Upon stimulation of SN-4 and SS-12 cells with Cry j I, IL-4 production, which was observed at the protein and the mRNA levels, was induced in an HLA-DR-restricted manner, using autologous and allogeneic antigen-presenting cells. In addition to IL-4, not only considerable amounts of IL-5 and IL-6 but also very small amounts of IL-2 and interferon-gamma (IFN-gamma) were secreted by SN-4 and SS-12 cells, indicating that they fit into the Th2-like phenotype. The culture supernatant from Cry j I-activated SN-4 cells had the ability to induce IL-4-dependent IgE synthesis, CD23 expression and soluble CD23 release. Moreover, Cry j I-dependent IgE synthesis medated by SN-4 cells derived from 1 patient expressing HLA-DRw8, w9 could be specifically induced in both autologous and HLA-DRw9-matched allogeneic B cell cultures. This IgE induction was inhibited by neutralizing antibodies to IL-4, IL-5 and IL-6, but was not enhanced by anti-IFN-gamma antibody. On the other hand, neither IL-4 production nor IgE synthesis was induced when SN-4 cells were cocultured in the presence of Cry j I with HLA-DRw8-matched or histoincompatible allogeneic cells.(ABSTRACT TRUNCATED AT 250 WORDS)
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1159/000236819 | DOI Listing |
Immunohorizons
January 2025
Department of Medical Microbiology and Infection Prevention, Amsterdam UMC location University of Amsterdam, Amsterdam, the Netherlands.
Atopic dermatitis (AD) is characterized by dysregulated T cell immunity and skin microbiome dysbiosis with predominance of Staphylococcus aureus, which is associated with exacerbating AD skin inflammation. Specific glycosylation patterns of S. aureus cell wall structures amplify skin inflammation through interaction with Langerhans cells (LCs).
View Article and Find Full Text PDFFood Res Int
February 2025
School of Food Science and Engineering, Qingdao Agricultural University, Qingdao 266109, PR China. Electronic address:
Food allergy poses a great challenge to food safety and public health worldwide. Currently, clinical symptoms are primarily managed with medications, which can lead to drug resistance, adverse effects, and disruptions in gut flora balance. As a result, there has been a focus on researching safe and effective anti-allergic natural ingredients.
View Article and Find Full Text PDFEur J Histochem
January 2025
Department of Dermatology, The Fifth People's Hospital of Hainan Province, Affiliated Dermatology Hospital of Hainan Medical University, Haikou, Hainan.
This study aimed to evaluate the therapeutic efficacy of camellia oil on 2,4-dinitrochlorobenzene (DNCB)-induced atopic dermatitis (AD) in mice, as well as its effect on the expression of skin-barrier-related proteins. A mouse model of AD was created via topical application of DNCB; subsequently, the animals were randomly divided into four groups: the blank control (Control), model (Model), moisturizing cream (Moisturizer), and camellia oil (Camellia) groups. The Camellia group received camellia oil, whereas the Moisturizer group was treated with moisturizing cream, as a positive control.
View Article and Find Full Text PDFArch Dermatol Res
January 2025
Department of Pediatrics, Faculty of Medicine, Srinakharinwirot University, HRH Princess Maha Chakri Sirindhorn Medical Center, Rangsit- Nakhonnayok Road, Ongkharak, Nakhonnayok, 26120, Thailand.
Acanthosis nigricans (AN) is a dermatological condition, marked by hyperpigmentation and skin thickening, frequently affecting body folds like the axillae. Treatment options for axillary hyperpigmentation remain underexplored. This study evaluated the efficacy of 0.
View Article and Find Full Text PDFMAbs
December 2025
St. John's Institute of Dermatology, School of Basic & Medical Biosciences & KHP Centre for Translational Medicine, Guy's Hospital, King's College London, London, UK.
Antibodies used for cancer therapy are monoclonal IgGs, but tumor-targeting IgE antibodies have shown enhanced effector cell potency against cancer in preclinical models. Research-grade recombinant IgE antibodies have been generated and studied for several decades. The recent Phase 1 clinical trial of the first-in-class MOv18 IgE, however, necessitated the inaugural process development and scaled manufacture of a recombinant IgE to clinical quality standards.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!